Complete responses to two different anti-PD1 agents in a metastatic melanoma patientComplete responsemelanomanivolumabpembrolizumabIn the last decade, immune checkpoint inhibitors changed the landscape of metastatic melanoma. However, the optimal duration of treatment and treatment cessation in responders is ...
Anti‐PD‐1/PD‐L1 agents play a crucial part in the treatment of non‐small cell cancer (NSCLC) demonstrating improved overall response rate (ORR) and overall survival (OS). Recent studies evaluating combination treatment with anti‐PD‐1 and anti‐CTLA‐4 suggests improved outcome but also ...
While dMMR patients benefit from the incorporation of both anti PD-1 or anti PD-L1, the gain in PFS is restricted to the incorporation of anti-PD1 agents in dMMR patients. Further analysis from updated trials is awaited to clarify the impact of immunotherapy on overall survival. Funding ...
Several antibodies that inhibit the PD-1 pathway by blocking either PD-1 or PD-L1 are being developed for clinical use in a variety of tumour types and clinical settings (Table 1). These agents differ in structure and are generally classified into two groups: anti-PD1 and anti-PD-L1 antib...
77 Nevertheless, the relative efficacy and toxicity of anti-PD-1 and anti-PD-L1 agents at present appear to be quite similar, and further work is necessary to delineate the potential differences in efficacy and toxicities of these agents. In addition to using monoclonal antibodies targeting the ...
Tumor extracellular matrix has been associated with drug resistance and immune suppression. Here, proteomic and RNA profiling reveal increased collagen levels in lung tumors resistant to PD-1/PD-L1 blockade. Additionally, elevated collagen correlates with decreased total CD8+T cells and increased exhaust...
“don't eat me” signal for macrophages. Disruption of CD47‐SIRPα signaling in the presence of prophagocytic signals can lead to enhanced phagocytosis of tumor cells, resulting in a direct antitumor effect; agents targeting this pathway have shown efficacy in non‐Hodgkin lymphoma (NHL) and ...
In conclusion, this report provides the first assessment of safety and efficacy of resuming anti-PD-1 agents following toxicity with dual PD-1 and CTLA-4 blockade. Approximately 40% of patients who resumed anti-PD-1 developed clinically significant recurrent or distinct irAEs. These toxicities oft...
Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes Introduction Although immune checkpoint inhibitors (ICI) in combination with hypomethylating agents (HMA) have had limited activity in acute ...
In further embodiments, the anti-PD-1 antibodies and fragments thereof bind to PD-1 and disrupt the PD-1/PD-L1 or PD1/PD-L2 pathway. In one embodiment, the antibody or fragment thereof is a murine antibody, a chimeric antibody, a human antibody or a humanized antibody. In one ...